Alkermes Plc (ALKS) Expected to Announce Earnings of -$0.06 Per Share
Wall Street analysts expect that Alkermes Plc (NASDAQ:ALKS) will announce earnings per share (EPS) of ($0.06) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Alkermes’ earnings, with estimates ranging from ($0.12) to ($0.02). Alkermes reported earnings of $0.03 per share during the same quarter last year, which indicates a negative year over year growth rate of 300%. The business is scheduled to issue its next quarterly earnings results before the market opens on Tuesday, October 23rd.
According to Zacks, analysts expect that Alkermes will report full year earnings of $0.09 per share for the current year, with EPS estimates ranging from $0.00 to $0.12. For the next year, analysts anticipate that the firm will post earnings of $0.50 per share, with EPS estimates ranging from ($0.01) to $0.89. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Alkermes.
Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Thursday, July 26th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.40. Alkermes had a negative return on equity of 0.29% and a negative net margin of 13.81%. The business had revenue of $304.64 million for the quarter, compared to analysts’ expectations of $261.58 million. During the same quarter in the prior year, the business earned $0.01 EPS. The firm’s revenue for the quarter was up 39.2% on a year-over-year basis.
ALKS traded down $0.64 during trading hours on Friday, reaching $40.16. The company’s stock had a trading volume of 634,166 shares, compared to its average volume of 722,046. Alkermes has a 52 week low of $38.23 and a 52 week high of $71.22. The company has a current ratio of 2.92, a quick ratio of 2.62 and a debt-to-equity ratio of 0.24. The stock has a market cap of $6.24 billion, a PE ratio of -108.54 and a beta of 1.72.
In other Alkermes news, Director Paul J. Mitchell sold 1,000 shares of the stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $44.58, for a total transaction of $44,580.00. Following the transaction, the director now owns 8,000 shares in the company, valued at approximately $356,640. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 3,000 shares of company stock worth $130,680 in the last quarter. Company insiders own 5.34% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. Baird Financial Group Inc. bought a new position in Alkermes during the 1st quarter worth $206,000. NumerixS Investment Technologies Inc bought a new position in Alkermes during the 2nd quarter worth $233,000. Clarus Wealth Advisors increased its position in Alkermes by 46.2% during the 3rd quarter. Clarus Wealth Advisors now owns 5,700 shares of the company’s stock worth $242,000 after buying an additional 1,800 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Alkermes during the 1st quarter worth $333,000. Finally, Verition Fund Management LLC bought a new position in Alkermes during the 1st quarter worth $363,000.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes.
Recommended Story: Moving Average (MA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.